Recursion Pharmaceuticals, Inc.
RXRX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $74.7M | $58.8M | +26.9% |
| Operating income | −$648M | −$479M | −35.3% |
| Net income | −$645M | −$464M | −39.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 2, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $18.6M | $5.20M | +258% |
| Operating income | −$123M | −$172M | +28.5% |
| Net income | −$119M | −$162M | +26.7% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Recursion's revenue in FY2025?
- $74.7M in FY2025 (Fiscal year ended Dec 31, 2025), +26.9% vs $58.8M a year earlier, per its 10-K filed Feb 2026.
- Was Recursion profitable in FY2025?
- No: net income was −$645M and operating income −$648M in FY2025.
- What was Recursion's revenue in Q3 2026?
- $18.6M (+258% vs a year earlier), per its Form 10-Q filed Nov 2, 2026.